预约演示
更新于：2026-02-06
Flomoxef Sodium
氟氧头孢钠
更新于：2026-02-06
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1988-03-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H18F2N6NaO7S2 |
InChIKeySYHZUFMYQQRMKT-YLCXCWDSSA-N |
CAS号92823-03-5 |
关联
2
项与 氟氧头孢钠 相关的临床试验JPRN-jRCTs061190025
Exploratory study on pharmacokinetics and optimum dosing regimen of cefmetazole, flomoxef and ceftolozane-tazobactam as prophylaxis for surgical site infection by ESBL-producing Escherichia coli after lower gastrointestinal surgery
NCT02302092
A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With Complicated Urinary Tract Infections Including Pyelonephritis
100 项与 氟氧头孢钠 相关的临床结果
登录后查看更多信息
100 项与 氟氧头孢钠 相关的转化医学
登录后查看更多信息
100 项与 氟氧头孢钠 相关的专利（医药）
登录后查看更多信息
470
项与 氟氧头孢钠 相关的文献（医药）2025-12-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Development of two methods for detecting Streptococcus mitis/oralis-related species with meropenem-non-susceptibility
Article
作者: Kimura, Kouji ; Shibayama, Keigo ; Kinoshita-Daitoku, Ryo ; Kuri, Kazuto ; Arakawa, Yoshichika
Several studies have reported clinical isolates of Streptococcus mitis, Streptococcus oralis, and their related species (S. mitis/oralis group) with reduced carbapenem susceptibility. However, to date, no simple and accurate methods of detecting S. mitis/oralis group isolates with reduced carbapenem susceptibility have been reported. The meropenem ETEST misinterpreted 3 of 25 (12 %) meropenem-non-susceptible S. mitis/oralis group isolates as susceptible to meropenem. Therefore, we screened 38 disks containing 38 different β-lactams to detect S. mitis/oralis group strains with reduced carbapenem susceptibility using the disk-diffusion method. Additionally, using the agar dilution method to determine susceptibility, we identified the optimal antibiotic concentrations in agar medium to enable selective culture of meropenem-non-susceptible S. mitis/oralis group by culturing 25 meropenem-non-susceptible (meropenem minimum inhibitory concentration [MIC] >0.5 μg/mL) and 24 meropenem-susceptible (meropenem MIC ≤0.5 μg/mL) S. mitis/oralis group isolates on agar containing different concentrations of six β-lactams. Meropenem-susceptible and non-susceptible S. mitis/oralis group isolates were successfully differentiated using oxacillin- and cefoxitin-containing disks. Moreover, cefdinir-, flomoxef-, meropenem-, and doripenem-containing disks showed clear differences in the growth inhibitory zone diameter between the meropenem-susceptible and meropenem-non-susceptible S. mitis/oralis group isolates. Media containing 2 μg/mL oxacillin, 4-16 μg/mL cefoxitin, 2 μg/mL cefdinir, 2-4 μg/mL flomoxef, 0.06-0.25 μg/mL meropenem, and 0.06-0.12 μg/mL doripenem allowed selective culture of meropenem-non-susceptible S. mitis/oralis group strains. The disk-diffusion method using six β-lactam-containing disks and selective culture agar medium are the first-reported simple and accurate methods of detecting meropenem-non-susceptible S. mitis/oralis group suitable for use in clinical microbiology laboratories.
2025-05-01Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Analysis of the therapeutic efficacy of bacterial infections through medical big data
Article
作者: Ishizawa, Keisuke ; Niimura, Takahiro ; Goda, Mitsuhiro
In recent years, many studies have been conducted on various diseases to evaluate clinical efficacy reflecting actual clinical conditions through comprehensive analysis using medical big data, which include various patient groups and factors in clinical practice. On the other hand, there are still very few research reports in the world related to the treatment of infectious diseases using medical big data. This is due to the fact that much medical big data lacks information on the causative organisms of infectious diseases and on determining the effectiveness of infectious disease treatment. In this paper, we introduce a research case study in which analysis on the effectiveness of infectious disease treatment was conducted using medical big data. In this study, we performed a retrospective analysis of two real databases with the aim of validating the usefulness of cefmetazole and flomoxef in urinary tract infections (UTI) in which broad-spectrum β-lactamase (ESBL)-producing bacteria are the primary initiating organisms. Third-generation cephalosporin-resistant E. coli and K. pneumoniae, including ESBL-producing strains, were similarly susceptible to flomoxef and cefmetazole. JMDC Claims data analysis showed that the median time of hospital stay duration was significantly shorter in the flomoxef group than in the cefmetazole group. Flomoxef exhibits effectiveness that is comparable to cefmetazole in treating UTI. When using currently available medical big data to conduct analyses related to infectious disease treatment, valuable analysis results may be obtained by understanding the characteristics of the database and collaborating with clinicians who are familiar with infectious disease treatment.
2025-03-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Clinical and microbiological characteristics of granulomatous mastitis caused by Corynebacterium species: A case series
Article
作者: Omori, Keitaro ; Nomura, Toshihito ; Kashiyama, Seiya ; Tadera, Kayoko ; Shigemoto, Norifumi ; Hara, Toshinori ; Mokuda, Sho ; Nagaoka, Rie ; Omoto, Takuji ; Kuhara, Yuta ; Ohge, Hiroki ; Koba, Yumiko ; Kitagawa, Hiroki
Corynebacterium species are an important cause of granulomatous mastitis (GM). Although there have been worldwide reports of infections caused by Corynebacterium kroppenstedtii, few cases of C. tuberculostearicum GM have been reported. We conducted a retrospective study to investigate the clinical and microbiological characteristics of GM caused by Corynebacterium spp. between January 1, 2014, and May 31, 2024. During the study period, six patients with GM were identified, including four cases of C. kroppenstedtii GM and two cases of C. tuberculostearicum GM. All patients were female with a median age of 32 years (range: 18-50 years). All patients underwent surgical drainage and were treated with clarithromycin. The minimum inhibitory concentration (MIC) values for various antimicrobial agents, including azithromycin, clarithromycin, ciprofloxacin, clindamycin, and trimethoprim-sulfamethoxazole, were higher for C. tuberculostearicum than for C. kroppenstedtii. Additionally, MALDI-TOF MS and 16s rRNA gene sequencing accurately identified C. kroppenstedtii and C. tuberculostearicum. Accurate identification of lipophilic Corynebacterium spp. is important for antibiotic treatment selection. If clinicians suspect lipophilic Corynebacterium spp. infection, particularly GM, they should ask the microbiology laboratory to test for lipophilic Corynebacterium spp.
100 项与 氟氧头孢钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌感染 | 日本 | 1988-03-29 |
登录后查看更多信息
临床结果
临床结果
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用